Jeremy Er

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

Author Correction: In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditions.

Author Correction: In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditions.

Journal: Nature communications

Published: October 03, 2025

Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.

Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.

Journal: Advances in therapy

Published: October 03, 2025

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics.

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics.

Journal: Blood

Published: February 19, 2025

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: February 12, 2025

Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.

Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 10, 2024

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Journal: Nature genetics

Published: November 07, 2024

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.

Journal: Current medical research and opinion

Published: August 12, 2024

In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditions.

In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditions.

Journal: Nature communications

Published: July 11, 2024

Infectious complications of bispecific antibody therapy in patients with multiple myeloma.

Infectious complications of bispecific antibody therapy in patients with multiple myeloma.

Journal: Blood cancer journal

Published: December 11, 2022

Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.

Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.

Journal: Cancers

Published: August 08, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026